Ortin Global Limited accepted the resignation of Mrs. Prakruti Prashant Sawant from the post of Whole-time Director, effective September 7, 2026. The board approved the move during its meeting held on the same date.

Mrs. Sawant cited professional commitments as the reason for her departure. In her resignation letter dated September 7, 2026, she confirmed that there were no other material reasons for stepping down. The company will submit the necessary forms to the Registrar of Companies (ROC) and stock exchanges.

Board Restructuring Details

This resignation is part of a broader restructuring of the board of directors approved on September 7, 2026. The changes include the appointment of a new Managing Director and the transition of the outgoing MD.

Mr. Prakash Prashanth Sawant has been appointed as Managing Director for a three-year term, effective from September 7, 2026, until September 6, 2029. This appointment is subject to shareholder approval at the upcoming AGM.

Concurrently, Mr. Murali Krishna Murthy Sanka will step down from his role as Managing Director to become a Non-Executive Director, effective immediately. His new designation is also subject to member approval.

New Appointments

Mr. Parveen Satija was appointed as an Additional Director and Whole-time Director for a two-year term, running from September 7, 2026, to September 6, 2028. This appointment requires ratification by shareholders.

Mr. Satija brings experience in corporate leadership, governance, and statutory compliance. He currently holds 1,00,526 equity shares in the company. The board affirmed that he is not debarred from holding office under any SEBI order.

AGM Schedule

The company’s 39th Annual General Meeting for FY26 will be conducted via video conference or other audio-visual means (OAVM). The meeting is scheduled for Wednesday, September 30, 2026, at 5:00 pm.

The agenda includes the approval of the director designation changes outlined above, alongside the standard consideration of the Directors’ Report for the financial year ending March 31, 2026.

Ortin Global Limited has clarified to the National Stock Exchange of India Limited that the requirement for reporting segment details is not applicable to the company. The firm stated it operates in only one segment, Drugs and Medicines. This disclosure was made in response to an exchange query regarding the financial results for the quarter and year ended March 31, 2026.

The National Stock Exchange of India Limited had sought clarification on June 27, 2026, specifically regarding the absence of segment details in the filing. In its reply dated July 9, 2026, the company explained that since it does not have multiple reportable business segments, the specific disclosure requirement does not apply to its financial reporting structure.

The communication was signed by S. Murali Krishna Murthy, Managing Director of Ortin Global Limited. The company confirmed that its entire operations fall under the Drugs and Medicines category, thereby exempting it from the detailed segment reporting standards applicable to multi-business entities.